Movement Alert｜HANSOH PHARMA Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure

Market Focus07-30

On July 30, HANSOH PHARMA fell 3.04% in regular trading, trading at HK$32.5/share, with turnover of HK$271 million. The decline came one session after the stock surged over 5% following its HS-20093 osteosarcoma Phase 3 trial success announcement.

The broader pharmaceutical sector exhibited notable weakness on the day. Among major peers, CSPC Pharma fell 3.08%, SBP Group fell 3.63%, Hengrui Pharma fell 2.32%, and Asymchem dropped 7.48%, while Sunshine Pharma bucked the trend with a 5.58% gain. The sector-wide selling pressure contributed to the pullback in HANSOH PHARMA shares.

On the news front, the company announced on July 28 that its proprietary B7-H3-targeted antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase 3 trial for relapsed or refractory osteosarcoma, demonstrating statistically significant improvement in progression-free survival versus chemotherapy. The company is preparing to file for regulatory approval in China. CLSA maintained an Outperform rating and raised its target price to HK$42, citing expectations for five new drug approvals next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183864516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 13:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183864516","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure","media":"Market Focus","content":"<p><p>On July 30, HANSOH PHARMA fell 3.04% in regular trading, trading at HK$32.5/share, with turnover of HK$271 million. The decline came one session after the stock surged over 5% following its HS-20093 osteosarcoma Phase 3 trial success announcement.</p><p>The broader pharmaceutical sector exhibited notable weakness on the day. Among major peers, CSPC Pharma fell 3.08%, SBP Group fell 3.63%, Hengrui Pharma fell 2.32%, and Asymchem dropped 7.48%, while Sunshine Pharma bucked the trend with a 5.58% gain. The sector-wide selling pressure contributed to the pullback in HANSOH PHARMA shares.</p><p>On the news front, the company announced on July 28 that its proprietary B7-H3-targeted antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase 3 trial for relapsed or refractory osteosarcoma, demonstrating statistically significant improvement in progression-free survival versus chemotherapy. The company is preparing to file for regulatory approval in China. CLSA maintained an Outperform rating and raised its target price to HK$42, citing expectations for five new drug approvals next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 13:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, HANSOH PHARMA fell 3.04% in regular trading, trading at HK$32.5/share, with turnover of HK$271 million. The decline came one session after the stock surged over 5% following its HS-20093 osteosarcoma Phase 3 trial success announcement.</p><p>The broader pharmaceutical sector exhibited notable weakness on the day. Among major peers, CSPC Pharma fell 3.08%, SBP Group fell 3.63%, Hengrui Pharma fell 2.32%, and Asymchem dropped 7.48%, while Sunshine Pharma bucked the trend with a 5.58% gain. The sector-wide selling pressure contributed to the pullback in HANSOH PHARMA shares.</p><p>On the news front, the company announced on July 28 that its proprietary B7-H3-targeted antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase 3 trial for relapsed or refractory osteosarcoma, demonstrating statistically significant improvement in progression-free survival versus chemotherapy. The company is preparing to file for regulatory approval in China. CLSA maintained an Outperform rating and raised its target price to HK$42, citing expectations for five new drug approvals next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1183864516","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183864516","pubTimestamp":1785388479,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, HANSOH PHARMA fell 3.04% in regular trading, trading at HK$32.5/share, with turnover of HK$271 million. The decline came one session after the stock surged over 5% following its HS-20093...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势警报|豪森制药常规交易下跌3.04%，医药板块普遍承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 30, HANSOH PHARMA fell 3.04% in regular trading, trading at HK$32.5/share, with turnover of HK$271 million. The decline came one session after the stock surged over 5% following its HS-20093 osteosarcoma Phase 3 trial success announcement.The broader pharmaceutical sector exhibited notable weakness on the day. Among major peers, CSPC Pharma fell 3.08%, SBP Group fell 3.63%, Hengrui Pharma fell 2.32%, and Asymchem dropped 7.48%, while Sunshine Pharma bucked the trend with a 5.58% gain. The sector-wide selling pressure contributed to the pullback in HANSOH PHARMA shares.On the news front, the company announced on July 28 that its proprietary B7-H3-targeted antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase 3 trial for relapsed or refractory osteosarcoma, demonstrating statistically significant improvement in progression-free survival versus chemotherapy. The company is preparing to file for regulatory approval in China. CLSA maintained an Outperform rating and raised its target price to HK$42, citing expectations for five new drug approvals next year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183864516","isCrawlerRequest":true}